Zolmitriptan. Antimigraine, 5-HT(1D) agonist

Drugs of the Future

Volumn 22, Issue 3, 1997, Pages 260-269

  Ngo, J ^a   Mealy, N ^a   Castaner J ^a  

^a PROUS SCIENCE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMIGRAINE AGENT; SEROTONIN 1D RECEPTOR; SEROTONIN AGONIST; SUMATRIPTAN; ZOLMITRIPTAN;

ASTHENIA; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SYNTHESIS; HEART PALPITATION; HUMAN; MIGRAINE; NAUSEA; NONHUMAN; ORAL DRUG ADMINISTRATION; SHORT SURVEY; SOMNOLENCE; TACHYCARDIA; THORAX PAIN; VERTIGO;

EID: 0030983346     PISSN: 03778282     EISSN: None     Source Type: Journal    
DOI: 10.1358/dof.1997.022.03.399409     Document Type: Short Survey

References (63)

1. Robertson, A.D., Hill, A.P., Glen, R.C., Martin, G.M. (The Wellcome Found., Ltd.). Therapeutic heterocyclic cpds. EP 486666, US 5466699, WO 9118897.
2. 1D receptor: Discovery of compounds with potential anti-migraine properties. J Med Chem 1995, 38: 3566-80.
3. Stewart, W.F., Lipton, R.B., Celentano, D.D., Reed, M.L. Prevalence of migraine headache in the United States. Relation to age, income, race, and other sociodemographic factors. JAMA 1992, 267: 64-9.
4. Lipton, R.B., Stewart, W.F. Migraine in the United States: Epidemiology and health care utilization. Neurology 1993, 43(Suppl. 3): 6-10.
5. Osterhaus, J.T., Gutterman, D.L., Plachetka, J.R. Healthcare resources and lost labour costs of migraine headaches in the US. PharmacoEconomics 1992, 2: 67-76.
6. Stang, P.E., Osterhaus, J.T. Impact of migraine in the United States: Data from the National Health Interview Survey. Headache 1993, 33: 29-35.
7. 1-like receptor agonists and the pathophysiology of migraine. Trends Pharmacol Sci 1989, 10: 200-4.
8. Moskowitz, M.A. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol Sci 1992, 13: 307-11.
9. Moskowitz, M.A. The neurology of vascular headache pain. Ann Neurol 1984, 16: 157-68.
10. Lance, J.W. 5-Hydroxytryptamine and its role in migraine. Eur J Neurol 1991, 31: 279-81.
11. Raskin, N.H.H. Serotonin receptors and headache. New Engl J Med 1991, 325: 353-4.
12. Humphrey, P.P.A., Feniuk, W., Perren, M.J. Anti-migraine drugs in development: Advances in serotonin receptor pharmacology. Headache 1990, 30(Suppl. 1): 12.
13. Humphrey, P.P.A. 5-Hydroxytryptamine and the pathophysiology of migraine. J Neurol 1991, 238: S38-44.
14. In: Migraine and other Headaches. Frontiers in Headache Research Series, Vol. 1, J. Olsen (Ed.), Raven Press, New York, 1991.
15. Peroutka, S.J. Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990, 8: 829-38.
16. Peroutka, S.J. The pharmacology of current antimigriane drugs. Headache 1990, 30(Suppl. 1): 5-11.
17. Silberstein, S.D. Review. Serotonin 5-HT and migraine. Headache 1994, 34: 408-17.
18. 1D receptor agonists in development. 6th Int Headache Res Semin Headache Treat Trial Methodol New Drugs (Nov 17-19, Copenhagen) 1995, 46.
19. 1D receptor agonist 311C90. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 3-4.
20. Martin, G.R., Dixon, R.M. Preclinical and clinicalpharmacology of the novel antimigraine compound, 311C90. 6th Int Headache Res Semin Headache Treat Trial Methodol New Drugs (Nov 17-19, Copenhagen) 1995, 52.
21. 1D receptor agonist 311C90. Headache 1994, 34: 394-9.
22. 1B/D receptor agonist zolmitriptan (311C90): Are brain stem sites therapeutic target in migraine? Pain 1996, 67: 355-9.
23. Hoskin, K.L., Knight, Y.E., Goadsby, P.J. Zolmitriptan inhibits c-fos expression in the dorsal horn of the medulla and upper cervical horn evoked by sagittal sinus stimulation in the cat. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 1.
24. 3H]BRL43694. Cephalalgia 1995, 15(Suppl. 14): Abst P11.
25. 1B/D receptor agonists in the anesthetized rat. Cephalalgia 1995, 15(Suppl. 14): Abst P7.
26. Martin, G.R., Dixon, R.M. Preclinical and clinical pharmacology of the novel antimigraine compound, 311C90. Headache 1995, 35(5): Abst 17.
27. Ferrari, M.D., Martin, G.R., Earl, N.L., Klein, K.B. Emerging preclinical and clinical profile of 311C90: A poster review and discussion. Eur Neurol 1996, 36(Suppl. 2): 19-23.
28. Seaber, E., On, N., Dixon, R., Phillips, S., Posner, J., Rolan, P. The pharmacokinetics of and tolerability to the novel antimigraine compound 311C90 in healthy male volunteers. Headache 1995, 35(5): Abst 23.
29. Dixon, R., On, N., Seaber, E., Rolan, P., Posner, J. Lack of an interaction between 311C90, a novel antimigraine compound, and oral ergotamine in healthy subjects. Headache 1995, 35(5): Abst 24.
30. Seaber, E., On, N., Dixon, R., Posner, J. The metabolic disposition of the novel antimigraine compound 311C90. Cephalalgia 1995, 15(Suppl. 14): Abst P13.
31. Seaber, E., On, N., Jackson, S., Dixon, R., Watt, H., Posner, J. Similar pharmacokinetics and tolerability of the novel antimigraine compound 311C90 in young and elderly volunteers. Cephalalgia 1995, 15(Suppl. 14): Abst P14.
32. 1D agonist, 311C90. Cephalalgia 1995, 15(Suppl. 14): Abst P16.
33. Smith, D.A., Phillips, L., Fleck, R.J., Lasseter, K.C., Shamblen, S., Adam, K.D. 311C90 in normotensive and mild to moderate hypertensive volunteers: A pharmacodynamic and pharmacokinetic comparison. Cephalalgia 1995, 15(Suppl. 14): Abst P17.
34. Thomsen, L.L., Dixon, R., Lassen, L.H., Gibbens, M., Langemark, M., Bendtsen, L., Daugaard, D., Olesen, J. 311C90 (zolmitriptan), a novel centrally and peripheral acting oral 5-hydroxytryptamine-1D agonist: A comparison of its absorption during a migraine attack and in a migraine-free period. Cephalalgia 1996, 16: 270-5.
35. Sweet, R., Klein, K.B. 311C90 is effective in good, fair and poor responders to existing therapies for acute migraine. Cephalalgia 1995, 15(Suppl. 14): Abst P21.
36. Schoenen, J., Caekebeke, J., Louis, P., Monseu, G., Phillips, S., Pierre, P. An open study to investigate the absorption and tolerability of oral 311C90 and to obtain a preliminary indication of efficacy in migraine patients. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 11-2.
37. Peck, R., Dixon, R., Seaber, E., On, N., Mercer, J., Posner, J., Rolan, P.E. Clinical pharmacology of 311C90. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 9-10.
38. Visser, W.H., Klein, K.B., Cox, R., Marks, S.J., Ferrari, M.D. An in-patient, placebo-controlled, dose-ranging study of oral 311C90 in the acute treatment of migraine. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 15-6.
39. Dahlöf, C., Diener, H.C., Goadsby, P., Massiou, H., Olesen, J., Schoenen, J., Wilkinson, M., Sweet, R.M., Klein, K.B. A multicentre, double-blind, placebo-controlled, dose-ranging study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 17-8.
40. Earl, N.L. The novel antimigraine compound 311C90: Overview of safety. Headache 1995, 35(5): Abst 20.
41. Klein, K.B. 311C90, a new acute treatment for migraine: An efficacy overview. Cephalalgia 1995, 15(Suppl. 14): 175.
42. Earl, N.L. Clinical safety of 311C90: Aggregated data from patients and volunteers to date. Eur Neurol 1996, 36(Suppl. 2): 8-12.
43. Giorgi, L., Dixon, R., Touw, K. Cardiovascular safety of the novel antimigraine compound 311C90. Cephalalgia 1995, 15(Suppl. 14): Abst P18.
44. Dahlof, C., Diener, H.C., Goadsby, P.J., Massiou, H., Olesen, J., Schoenen, J., Wilkinson, M., Sweet, R.M., Klein, K.B. A multicenter, double-blind placebo-controlled, dose-range finding study to investigate the efficacy and safety of oral doses of 311C90 in the acute treatment of migraine. Headache 1995, 35(5): Abst 19.
45. Lowy, M.T., Kench, S., Miles, P. Evaluation of the long-term safety and efficacy of 311C90 in the treatment of migraine. Cephalalgia 1995, 15(Suppl. 14): Abst P20.
46. Giorgi, L., Seaber, E., Smith, D.A., Dixon, R., Layton, G., Peck, R. W. 311C90 has no clinically significant effects on blood pressure. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 109.
47. Schoenen, J., Klein, K.B. 311C90 and sumatriptan produce indistinguishable CNS adverse event profiles. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 86.
48. Zagami, A., Fletcher, P.E., Barrows, C., Lowy, M.T. Confirmation of the long-term safety and efficacy of oral 311C90 in the acute treatment of migraine: Demographic analysis from a study of > 20,000 treated attacks. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 111.
49. Silberstein, S.D., Fletcher, P.E., Lowy, M.T. Confirmation of the long-term safety of 311C90 in the acute oral treatment of migraine. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 42.
50. Rapoport, A.M., Cady, R.K., Matthew, N.T., Ramadan, N.M., Taylor, F.R., Saper, J.R., Earl, N.L., Brown, D.L. Optimizing the oral dose of 311C90 in the acute treatment of migraine. Cephalalgia 1995, 15(Suppl. 14): Abst P19.
51. Thomsen, L., Lassen, L., Bendtsen, L., Daugaard, D., Dixon, R., Olesen, J. An open, cross-over study to compare the absorption of a 10 mg oral dose of 311C90 during and outside a migraine attack and to obtain a preliminary indication of efficacy in migraine. In: New Advances in Headache Research: 4. Proceedings of the 10th Migraine Trust Symposium, London, September 1994, F. Clifford Rose (Ed.), Smith-Gordon, London, 1994, 13-4.
52. Ferrari, M.D. The clinical effectiveness of 311C90 in the acute treatment of migraine. Eur Neurol 1996, 36(Suppl. 2): 4-7.
53. Visser, W.H., Ferrari, M.D., Klein, K.B., Cox, R.C., Jones, D. An in-patient, placebo-controlled, dose-ranging study of oral 311C90 in the acute treatment of migraine. Headache 1995, 35(5): Abst 18.
54. Fletcher, P.E., Lowy, M.T. Confirmation of the long-term efficacy of 311C90 in the acute oral treatment of migraine. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 110.
55. 1D receptor agonist in the acute oral treatment of migraine: A double-blind, placebo-controlled, dose-range finding study. Neurology 1996, 46: 522-6.
56. Dalessio, D.J., Brown, D.L., Solbach, P., Adelman, J.U., Elkind, A.M., Stark, S.R. Oral 311C90 is effective in treatment of menstrual migraine. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 112.
57. Seaber, E., Dixon, R., Gillotin, C., Layton, G., Posner, J., Peck, R. The combination of 311C90, a novel antimigraine compound, and oral propranolol in healthy subjects. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 101.
58. Seaber, E., Mohanlal, R., Gillotin, C., Layton, G., Posner, J., Peck, R. Minimal interaction between 311C90, a novel antimigraine compound, and oral pizotifen. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 102.
59. Sweet, R.M., Brown, D.L., Walker, A. The high efficacy of 311C90 in treating migraine headache is maintained in patients using oral contraceptives. 11th Migraine Trust Int Symp (Sept 9-12, London) 1996, Abst 103.
60. Zeneca Group plc annual results. Zeneca Pharmaceuticals Press Release 1997, March 11.
61. Klein, K.B. Overview of the efficacy of zolmitriptan (311C90): A new acute treatment for migraine. 8th World Cong Pain (Aug 17-22, Vancouver) 1996, 499.
62. Earl, N.L. Overview of the safety of zolmitriptan (311C90): A new acute treatment for migraine. 8th World Cong Pain (Aug 17-22, Vancouver) 1996, 500.
63. 1D agonist for migraine acute treatment. New views on mechanisms of action. 8th World Cong Pain (Aug 17-22, Vancouver) 1996, 499.